Forecast: Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry in Canada

Analysis of the business enterprise expenditure on R&D in the Canadian pharmaceutical industry indicates a consistent expenditure represented by an anticipated steady share of 2.1% of GDP from 2024 to 2028, the same as forecasted for 2023. This consistent share of GDP suggests a stabilization without year-on-year percentage variation or annual growth observed through the forecast period.

Trends to watch for in the future include:

• Potential impacts from evolving healthcare policies in Canada that could influence R&D investment decisions in the pharmaceutical sector.
• Technological advancements driving efficiency in R&D processes, potentially affecting expenditure levels relative to GDP.
• Global economic conditions and their influence on the Canadian pharmaceutical industry’s financial capacity to maintain or adjust R&D investment levels.